Epidermal growth factor showed no clear difference in survival rates at 3 years compared with best supportive care (low certainty).
Epidermal growth factor may leads to higher survival rates at 5 years compared with best supportive care (low certainty).
It is very uncertain whether epidermal growth factor changes health‐related quality of life compared with best supportive care (very low certainty).
Epidermal growth factor showed no clear difference in overall survival compared with best supportive care (low certainty).
The review found no eligible studies for this question.
Epidermal growth factor showed no clear difference in participants with at least one serious adverse event compared with best supportive care (low certainty).
Erlotinib showed no clear difference in overall survival compared with control (high certainty).
Erlotinib leads to lower progression‐free survival compared with control (high certainty).
Gefitinib showed no clear difference in overall survival compared with paclitaxel + carboplatin (high certainty).
Gefitinib leads to lower progression‐free survival compared with paclitaxel + carboplatin (high certainty).
Gefitinib showed no clear difference in overall survival compared with pemetrexed + carboplatin with pemetrexed maintenance (moderate certainty).
Gefitinib probably leads to lower progression‐free survival compared with pemetrexed + carboplatin with pemetrexed maintenance (moderate certainty).
Afatinib showed no clear difference in overall survival compared with chemotherapy (high certainty).
Afatinib leads to lower progression‐free survival compared with chemotherapy (high certainty).
Anti‐EGFR therapy showed no clear difference in overall survival ‐ first‐line studies compared with placebo or standard of care (moderate certainty).
Anti‐EGFR therapy showed no clear difference in overall survival ‐ recurrent disease studies compared with placebo or standard of care (low certainty).
Anti‐EGFR therapy showed no clear difference in lymphopenia compared with placebo or standard of care (low certainty).
Anti‐EGFR therapy showed no clear difference in neutropenia compared with placebo or standard of care (low certainty).
Anti‐EGFR therapy showed no clear difference in thrombocytopenia compared with placebo or standard of care (low certainty).
Anti‐EGFR therapy showed no clear difference in progression‐free survival ‐ first‐line studies compared with placebo or standard of care (low certainty).